Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

compulsory licence

Roche's Perjeta pertuzumab

Roche’s Perjeta launches in UK for early breast cancer

Says nearly 2,000 women each year could benefit from its drug

- PMLiVE

Roche says Esbriet boosts survival in pulmonary fibrosis

Positive results due to be presented at European Respiratory Society 

- PMLiVE

National Audit Office agrees CDF is ‘unsustainable’

Says a replacement for the CDF is urgently needed

Roche Basel Switzerland

FDA grants Roche’s alectinib priority review for lung cancer

Expedited review given for ALK-positive lung cancer treatment

Bristol-Myers Squibb (BMS) building

Opdivo plus Yervoy effective first-line in lung cancer

Study shows immuno-oncology agents work well together

- PMLiVE

Cancer Drugs Fund axes 16 treatments after overspending

Medicines from Roche, Celgene, Merck KGaA and Janssen among those dropped

Bristol-Myers Squibb (BMS) building

BMS’ myeloma treatment accepted for priority review

If approved elotuzumab will be marketed as Empliciti

- PMLiVE

Industry files complaint against France’s off-label law

Protests against promotion of Roche's Avastin as cheap eye medication

- PMLiVE

Roche wins first approval for skin cancer drug Cotellic

Swissregulators give the Exelixis-discovered treatment the green light

Roche Basel Switzerland

Roche buys gene sequencing firm

Swiss firm has been working with Kapa for two years but is now acquiring the company

Roche Basel Switzerland

Roche’s PD-L1 drug shrinks lung tumours

Drug has already showed success in treating certain bladder cancer patients

Can Cinderella save us?

Roche buys GeneWeave to boost antibiotics portfolio

Swiss firm buys into a new diagnostic technology called ‘Smarticles’

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links